Adjuvant Chemotherapy for High Malignant Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study aims to evaluate the efficacy of adjuvant docetaxel chemotherapy following radical radiotherapy in patients with localized high-grade prostate cancer. Eligible participants include those diagnosed with prostate cancer confirmed by biopsy or surgical pathology, with a Gleason score of 9-10 or containing a Gleason 5 component, and no evidence of distant metastasis. Patients will be divided into two groups: the standard treatment group receiving only radical treatment (radiotherapy or surgery), and the standard treatment plus chemotherapy group, receiving four to six cycles of docetaxel chemotherapy after standard treatment. The primary endpoint is Failure-Free Survival (FFS), with secondary endpoints including Biochemical Relapse-Free Survival (BRFS), Metastasis-Free Survival (MFS), Overall Survival (OS), and assessment of adverse events The study aims to better understand the impact of adjuvant chemotherapy on the prognosis of patients with high-risk prostate cancer and determine whether it improves survival outcomes.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak prostaty (stopień 9-10 wg skali Gleasona lub zawierający składnik 5)
- •Brak przerzutów w innych częściach ciała potwierdzone badaniami obrazowymi
- •Kwalifikacja do standardowego leczenia (napromieniowanie lub operacja)
- •Oczekiwane przeżycie ponad 12 miesięcy
- •Wiek 18 lat lub więcej
- •Ogólny stan zdrowia pozwalający na leczenie (skala Karnofsky'ego minimum 80)
- •Prawidłowe wyniki morfologii krwi (liczba leukocytów, neutrofili i płytek krwi)
✗ Disqualifies
- •Historia innego nowotworu (chyba że wyleczony ponad 5 lat temu)
- •Poprzednie napromieniowanie brzucha
- •Utrata masy ciała powyżej 10% w ostatnich 6 miesiącach
- •Zaburzenia krzepnięcia krwi
- •Aktywne infekcje
- •Poważne choroby serca lub naczyniowe, które mogą uniemożliwić chemioterapię
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- August 20, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (3)
Peking University First Hospital
Beijing, China
Peking University Shenzhen Hospital
Shenzhen, China
Hebei Yi Zhou Cancer Hospital
Baoding, China
Trial contact
Yajie Liu
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.